Pharmacokinetic Study of MK-3475A in Patients with Advanced or Metastatic Solid Tumors

The primary objective of this study is to evaluate the **absorption** of MK-3475A in participants with advanced or metastatic **solid tumors**. Understanding the absorption characteristics of MK-3475A is clinically relevant as it may influence the drug's efficacy and safety profile, thereby impacting treatment outcomes for patients with these types of tumors.

The clinical trial involves a total of **113 participants** diagnosed with **advanced or metastatic solid tumors**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected to represent a diverse group, including vulnerable populations. The trial does not specify particular lifestyle considerations such as diet or physical activity. The selection process aimed to ensure a representative sample of the general population affected by the specified medical condition. The sponsor has not provided detailed information regarding the main objective or specific inclusion criteria for this study.

The clinical trial is designed to evaluate the **absorption** of MK-3475A in participants diagnosed with **advanced or metastatic solid tumors**. This study is structured as a Phase 3, randomized, double-blind, controlled trial, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thereby minimizing bias. The trial is expected to span approximately five years, with recruitment having commenced on September 21, 2021, and an estimated completion date of September 26, 2026.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be randomized into treatment groups. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health, assess the drug's absorption, and collect data on any adverse events. These visits are integral to ensuring participant safety and the collection of high-quality data.

The end-of-study visit marks the conclusion of a participant's involvement in the trial. During this visit, final assessments are conducted, and participants are debriefed. The expected length of participant involvement varies, but it is generally aligned with the trial's overall duration unless specific conditions necessitate early termination. Such conditions may include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed appropriate by the study investigators.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on the administration of other medicinal products or their role in the trial.

Furthermore, the documentation lacks information on the **product's authorization status**, pharmaceutical form, and the origin of the active substances. There is no mention of the sponsor product code or any specific product dictionary information.

Due to the absence of detailed data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be described. The trial documentation does not include any specific identifiers or objectives related to the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to conclude by September 26, 2026, with recruitment having commenced on September 21, 2021. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured methodology to ensure the accurate measurement and analysis of efficacy parameters. The data collection and analysis will adhere to rigorous standards typical of Phase 3 trials, ensuring the reliability and validity of the results. The trial's design and execution will be aligned with regulatory requirements and scientific best practices to evaluate the therapeutic benefits of the investigational product.